Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. NASDAQ:HOWL, according to a Form 4 filing with the Securities and Exchange Commission. The stock has recently taken a ...
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other ...
MPM BioVentures 2014, L.P. and related entities sold a total of 242,890 shares of Werewolf Therapeutics Inc. NASDAQ:HOWL common stock between November 4 and November 6, 2025, for approximately ...
Director Luke Evnin of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) recently sold a total of 199,356 shares of common stock in three separate transactions, netting approximately $251,348. The sale comes ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Plot Device: Ruby Glow Grinder. There’s plenty of buildup before the main event in Moronova’s dark romance, so this velvety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback